| ID | 1352 |
| Name of the vaccine | Tritanrix-HepB/ Hiberix |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 6 to 8 weeks |
| Description of the vaccine | Low or high dose formulations of DTPw-HBV/Hib vaccine. |
| Name of the manufacturer | GlaxoSmithKline |
| Name of the manufacturing country | India |
| Year of manufacture | 2008 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses at 6, 10 and 14 weeks of age. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For whole cell pertussis, diphtheria, tetanus and hepatitis B. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00473668 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|